Large-scale testing (Phase 3)Study completedNCT03924856
What this trial is testing
Perioperative Pembrolizumab (MK-3475) Plus Neoadjuvant Chemotherapy Versus Perioperative Placebo Plus Neoadjuvant Chemotherapy for Cisplatin-eligible Muscle-invasive Bladder Cancer (MIBC) (MK-3475-866/KEYNOTE-866)
Who this might be right for
Bladder Cancer
Merck Sharp & Dohme LLC 907